Objective. Several clinical studies have demonstrated the effectiveness of omalizumab in
patients with severe allergic asthma but the treatment period has always been relatively …

The ability of omalizumab, an anti-immnoglobulin‐E agent, to maintain long‐term disease
control in patients with moderate-to-severe allergic asthma was investigated in a 24‐week …

Introduction: Efficacy and safety of omalizumab in patients with severe allergic asthma has
been established in both randomized controlled trials and real-life studies Aim: To evaluate …

Omalizumab has been shown to be an effective add-on therapy for patients with
uncontrolled severe persistent allergic asthma. There has been a steady accumulation of …

BACKGROUND: Previous reports show that addition of omalizumab to standard therapy
reduces asthma exacerbations and simultaneously decreases use of inhaled corticosteroids …

Introduction Omalizumab is a high-cost therapy recommended for the treatment of severe
allergic asthma. Objective To find clinical parameters that are related to the sustained …

Rationale. Severe asthma is characterized by inadequate symptom control and by high rate
of inflammation despite high doses of steroids. Omalizumab, a recombinant humanized …

Introduction Currently, omalizumab is indicated for the treatment of patients with severe
allergic uncontrolled asthma despite optimal therapy. Case presentation We studied a 52 …

Objectives: The aim of this study was to assess the stability of the effectiveness of
omalizumab as add-on treatment in 11 patients with severe persistent allergic asthma …

Abstract Background Randomized Controlled Trials showed that omalizumab exhibited a
good safety and tolerability profile in patients with moderate-to-severe asthma. However …